Literature DB >> 11177727

Quinolone Resistance: Older Concepts and Newer Developments.

Darrin J. Bast1, Joyce C. S. de Azavedo.   

Abstract

New quinolone compounds have been recommended for use in the treatment of respiratory tract infections, particularly pneumonia caused by multi drug-resistant Streptococcus pneumoniae. Of concern, however, is the recent emergence of pneumococcal isolates with reduced susceptibilities to both old and new quinolone compounds. This necessitates the employment of quinolone-use strategies aimed at restricting the emergence of resistance, to extend the effectiveness of this very important class of antibacterial agents. This article provides a comprehensive review of the recent discoveries in type II topoisomerase/quinolone structure-function relationships. It also addresses new insights into the mechanisms of quinolone resistance, the predicted trends in quinolone resistance, and possible strategies for quinolone use against S. pneumoniae.

Entities:  

Year:  2001        PMID: 11177727     DOI: 10.1007/s11908-001-0055-y

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  73 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.

Authors:  F L Alovero; X S Pan; J E Morris; R H Manzo; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.

Authors:  B A Stewart; A P Johnson; N Woodford
Journal:  J Med Microbiol       Date:  1999-12       Impact factor: 2.472

Review 4.  Type II DNA topoisomerases.

Authors:  J M Berger
Journal:  Curr Opin Struct Biol       Date:  1998-02       Impact factor: 6.809

5.  Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.

Authors:  I Morrissey; J George
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

6.  Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.

Authors:  P D Lister; C C Sanders
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

7.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

Authors:  X Zhao; C Xu; J Domagala; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

8.  A fluoroquinolone antibiotic with a methoxy group at the 8 position yields reduced generation of 8-oxo-7,8-dihydro-2'-deoxyguanosine after ultraviolet-A irradiation.

Authors:  J E Rosen; D Chen; A K Prahalad; T E Spratt; G Schluter; G M Williams
Journal:  Toxicol Appl Pharmacol       Date:  1997-08       Impact factor: 4.219

Review 9.  Safety and tolerability of fluoroquinolones.

Authors:  S R Norrby; P S Lietman
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.

Authors:  J H Jorgensen; L M Weigel; M J Ferraro; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  1 in total

1.  Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  D J Bast; J C de Azavedo; T Y Tam; L Kilburn; C Duncan; L A Mandell; R J Davidson; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.